Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Accounts Payables (2023 - 2025)

Historic Accounts Payables for Compass Therapeutics (CMPX) over the last 3 years, with Q3 2025 value amounting to $3.1 million.

  • Compass Therapeutics' Accounts Payables rose 22239.58% to $3.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.1 million, marking a year-over-year increase of 22239.58%. This contributed to the annual value of $2.2 million for FY2024, which is 4501.22% down from last year.
  • Latest data reveals that Compass Therapeutics reported Accounts Payables of $3.1 million as of Q3 2025, which was up 22239.58% from $2.6 million recorded in Q2 2025.
  • Over the past 5 years, Compass Therapeutics' Accounts Payables peaked at $4.1 million during Q4 2023, and registered a low of $724000.0 during Q2 2023.
  • Moreover, its 3-year median value for Accounts Payables was $1.6 million (2025), whereas its average is $1.9 million.
  • Per our database at Business Quant, Compass Therapeutics' Accounts Payables plummeted by 5836.95% in 2024 and then soared by 22239.58% in 2025.
  • Over the past 3 years, Compass Therapeutics' Accounts Payables (Quarter) stood at $4.1 million in 2023, then plummeted by 45.01% to $2.2 million in 2024, then surged by 37.62% to $3.1 million in 2025.
  • Its Accounts Payables stands at $3.1 million for Q3 2025, versus $2.6 million for Q2 2025 and $1.6 million for Q1 2025.